Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dueno, Otto
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia	Terminated	3	452	Europe, US, RoW	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	11/23	11/23
OUTLAST, NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200	Terminated	2	61	US	IXT-m200, Placebo	InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)	Methamphetamine-dependence, Methamphetamine Abuse	09/23	11/23
NCT04948307: OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder	Completed	N/A	437	US	OXD01 digital therapy, Standard of Care	Orexo AB	Opioid-use Disorder	04/23	05/23